Hengrui Medicine

Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows

A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?

WIM2020: Insights on the Post-pandemic Outlook for the Healthcare Industry

The curtain came down on Dec 10 on the 'Healthtech Industry and COVID-19 Pandemic' Chapter at WIM 2020. Healthtech entrepreneurs and investors gathered to share insights on the outlook for the healthcare industry, covering topics like vaccination, AI healthcare, intelligent hardware, medical appliances and IVD.

WIM2020: Uniting the World through Technology and Innovation

On December 9-12, EqualOcean held the World Innovators Meet (WIM) 2020. This year, the event's main topic was 'Technology and Innovation Connect the World.' WIM2020 gathered innovators from Asia, Africa, Europe and North America to share their knowledge and key achievements, promoting the concept of 'Tech for Equal.'

CSPC Pharma’s Arthritis Painkiller Listed by China's Medical Agency

CSPC Pharmaceutical has seized the chance of entry into the third national centralized procurement and expects stable sales for the generic drug Celecoxib.

New Normal, New Policies: A Focus on Healthcare in Two Sessions 

The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.